Innate Pharma S.A. (EPA:IPH)
1.672
-0.008 (-0.48%)
At close: Dec 5, 2025
Innate Pharma Employees
Innate Pharma had 181 employees as of December 31, 2024. The number of employees increased by 2 or 1.12% compared to the previous year.
Employees
181
Change (1Y)
2
Growth (1Y)
1.12%
Revenue / Employee
€72,621
Profits / Employee
€264,661
Market Cap
154.10M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| EssilorLuxottica Société anonyme | 153,498 |
| Sanofi | 82,878 |
| Sartorius Stedim Biotech | 9,901 |
| bioMérieux | 14,754 |
| Eurofins Scientific SE | 62,696 |
| Ipsen | 5,358 |
| ABIVAX Société Anonyme | 69 |
| Virbac | 6,365 |
Innate Pharma News
- 8 days ago - Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025 - Business Wire
- 19 days ago - Innate Pharma to Present at Jefferies Global Healthcare Conference - Business Wire
- 22 days ago - Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Innate Pharma (IPHA) Reports Significant Revenue Decline in 9M 2025 - GuruFocus
- 23 days ago - Innate Pharma reports 9M results - Seeking Alpha
- 23 days ago - Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results - Business Wire
- 26 days ago - Innate Pharma (IPHA) Gains FDA Approval to Advance Phase 3 Lacutamab Trial - GuruFocus
- 26 days ago - Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL - Business Wire